Express News | Travere Therapeutics Inc : JP Morgan Cuts Target Price to $42 From $43

BreakingsNov 20 13:28

JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas

Seeking AlphaNov 20 00:06

Travere Therapeutics Is Maintained at Neutral by Piper Sandler

Dow JonesNov 14 22:28 · Ratings

Travere Therapeutics Analyst Ratings

BenzingaNov 14 22:17 · Ratings

Piper Sandler Maintains Travere Therapeutic(TVTX.US) With Hold Rating, Raises Target Price to $22

Futu NewsNov 14 20:34 · Ratings

Piper Sandler Reaffirms Their Hold Rating on Travere Therapeutics (TVTX)

TipRanksNov 14 20:16 · Ratings